PALO ALTO, Calif., June 14, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it received notification from SirtexMedical Limited (Sirtex) on June 14, 2018 that its board has determined that the proposal from CDH Investments and China Grand Pharmaceutical and Healthcare Holdings Limited (CDH-CGP Proposal) is a Superior Proposal
"Varian is very disciplined in its business development approach and we do not see value beyond the A$28 price per share we offered for Sirtex," said Dow Wilson, president and chief executive officer of Varian. "While disappointed with this decision, Varian's long-term strategy has not changed. We remain focused on becoming a global leader in multi-disciplinary, integrated cancer care solutions; expanding the addressable markets that Varian can impact; and growing and creating sustainable value for our company and our shareholders."
Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Mark PlungyDirector, Public Relations+1 (650) 424-5630 firstname.lastname@example.org
Investor Relations Contact
J. Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163 email@example.com
View original content:http://www.prnewswire.com/news-releases/varian-provides-update-on-proposed-sirtex-acquisition-300666424.html
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All